| 今开：27.14 | 昨收：27.08 |
| 最高：27.41 | 最低：26.28 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：1.850480947E9 |
美股律师郝俊波04-29 13:43
$Akero Therapeutics(AKRO)$ 【Akero Therapeutics(AKRO)最新证券集体诉讼】
Akero Therapeutics Inc(NASDAQ: AKRO)因证券欺诈案已经于近日被投资者集体诉讼至法院。在目前的诉讼中投资者指控该公司及部分高管在本案诉讼期间进行虚假陈述，违反证券法令投资者受损。投资者向法院申请判令被告...查看全文
Akero Therapeutics(AKRO)07-02 04:15
$Akero Therapeutics(AKRO)$ 144 Report of proposed sale of securities Accession Number: 0001968582-24-000576 Act: 33 Size: 6 KB 网页链接查看全文
Akero Therapeutics(AKRO)07-03 07:05
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080922 Size: 5 KB 网页链接查看全文
Akero Therapeutics(AKRO)06-12 05:35
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072077 Size: 5 KB 网页链接查看全文
Akero Therapeutics(AKRO)06-14 06:15
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-073183 Size: 5 KB 网页链接查看全文
Akero Therapeutics(AKRO)05-11 05:05
$Akero Therapeutics(AKRO)$ S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers Accession Number: 0001193125-24-136259 Act: 33 Size: 1 MB 网页链接查看全文
Akero Therapeutics(AKRO)06-14 06:15
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-073192 Size: 8 KB 网页链接查看全文
Akero Therapeutics(AKRO)07-03 07:05
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080924 Size: 5 KB 网页链接查看全文
Akero Therapeutics(AKRO)07-03 07:05
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080923 Size: 5 KB 网页链接查看全文
美股魔方2019-06-18 10:49
准备要上的NASH股$Akero Therapeutics(AKRO)$ ，只有一个药是一个靶向FGF21，带有Fc区域的融合蛋白，从安进获得授权。这个药阶段非常早，临床试验设计也是以验证为主；从使用上考虑，这个药必然采用注射的方式，治疗NASH这种慢性病并不方便；靶点上看起来主要针对纤维形成，估计对炎症保肝效果和降...查看全文
智通财经APP获悉，9月13日(周二)美股盘初，截至发稿，Akero Therapeutics(AKRO.US)股价走高，上涨112.39%，报26.06美元。消息面上，该公司表示，其药物efruxifermin (EFX)改善了肝纤维化，但没有加重肝脏疾病，达到了2b期研究的主要目标。 网页链接
智通财经APP获悉，Akero Therapeutics(AKRO.US)表示，其药物efruxifermin (EFX)改善了肝纤维化，但没有加重肝脏疾病，达到了2b期研究的主要目标。截至发稿，Akero Therapeutics周二盘前大涨120.05%，报27美元。 这项名为HARMONY的试验评... 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-084733 Size: 10 KB 网页链接
$Akero Therapeutics(AKRO)$ 144 Report of proposed sale of securities Accession Number: 0001974158-24-000054 Act: 33 Size: 5 KB 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080921 Size: 9 KB 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080922 Size: 5 KB 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080924 Size: 5 KB 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080923 Size: 5 KB 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-080926 Size: 5 KB 网页链接
$Akero Therapeutics(AKRO)$ 144 Report of proposed sale of securities Accession Number: 0001968582-24-000576 Act: 33 Size: 6 KB 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-073183 Size: 5 KB 网页链接
$Akero Therapeutics(AKRO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-073188 Size: 5 KB 网页链接